Phase 3 Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women who are pregnant with a single baby and are between 19 and 50 years old.
- Women who have at least one of the following in their pregnancy history: a previous pregnancy complicated by preeclampsia (high blood pressure during pregnancy), a previous pregnancy where the baby did not grow as expected, or a previous pregnancy where the baby died in the womb.
- Women who have been fully informed about the study and have agreed in writing to take part.
Who may not be able to join:
- People with serious conditions affecting the heart, immune system, lungs, digestive system, liver, kidneys, nervous system, muscles or joints, mental health, or those with infections or cancer — although the trial doctor may still allow participation if they consider it medically appropriate (confirm with trial site).
- People who have taken part in another treatment-based clinical trial within the 3 months before screening.
- People whose baby has been found to have a major physical abnormality at the 11–13 week scan.
- People with blood test results showing kidney function is significantly reduced, specifically creatinine levels more than double the upper limit of normal.
- People with blood test results showing liver enzyme levels (AST or ALT) more than three times the upper limit of normal.
- People with conditions that may make taking aspirin unsuitable, including: having taken aspirin or similar anti-inflammatory medicines (NSAIDs) in the 28 days before screening; having a bleeding disorder such as von Willebrand's disease or stomach ulcers; or having a known allergy or sensitivity to aspirin.
- People with conditions that may make taking hydroxychloroquine unsuitable, including: having taken hydroxychloroquine in the 28 days before screening; having a known allergy to hydroxychloroquine or related compounds; having a condition affecting the back of the eye (maculopathy); taking other medicines that may affect vision; having a personal risk of eye or vision changes from this type of medicine; having certain rare sugar-processing disorders (galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption); having a prolonged QT interval on a heart tracing (ECG), or conditions that raise the risk of this (such as heart failure, irregular heartbeat, or reduced blood supply to the heart); having low potassium levels in the blood; or having low magnesium levels in the blood.
- People whom the trial doctor considers unsuitable for participation based on their medical assessment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yoo-min Kim, MD, Chung-Ang University Gwangmyeong Hospital
Phone: +82-2-6299-1661
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite morbidity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.